Author Affiliations: Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia.
Plasma levels of high-density lipoprotein cholesterol (HDL-C) and its
major protein apolipoprotein A-I (apoA-I) are consistently inversely associated
with coronary heart disease (CHD) risk in observational studies.1 Furthermore,
studies in animals over the last 2 decades have established that intravenous
infusion of HDL or apoA-I or genetic overexpression of apoA-I can substantially
reduce the progression and even induce regression of preexisting atherosclerosis.2 Based on these data, HDL and apoA-I have become a
major target for the development of new therapies for atherosclerosis.3,4
Rader DJ. High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis. JAMA. 2003;290(17):2322–2324. doi:10.1001/jama.290.17.2322
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: